Interindividual variability of carboxymethylenebutenolidase homolog, a novel olmesartan medoxomil hydrolase, in the human liver and intestines

Drug Metabolism and Disposition

Volumn 41, Issue 5, 2013, Pages 1156-1162

  Ishizuka, Tomoko ^a   Rozehnal, Veronika ^a   Fischer, Thomas ^a   Kato, Ayako ^a   Endo, Seiko ^a   Yoshigae, Yasushi ^a   Kurihara, Atsushi ^a   Izumi, Takashi ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYMETHYLENEBUTENOLIDASE; MUTANT PROTEIN; OLMESARTAN; OXYGENASE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ALLELE; ARTICLE; COLON; CONTROLLED STUDY; DRUG STRUCTURE; DUODENUM; ENZYME ACTIVITY; FEMALE; GENETIC ENGINEERING; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTESTINE; JEJUNUM; LIVER; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; WILD TYPE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BASE SEQUENCE; CARBOXYLIC ESTER HYDROLASES; DNA PRIMERS; FEMALE; HUMANS; INTESTINES; LIVER; MALE; MIDDLE AGED; RNA, MESSENGER; YOUNG ADULT;

EID: 84876759090     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.113.051482     Document Type: Article

References (30)

1. Beaumont K, Webster R, Gardner I, and Dack K (2003) Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: Challenges to the discovery scientist. Curr Drug Metab 4:461-485.
2. Chrysant SG (2008) Amlodipine/ARB fixed-dose combinations for the treatment of hypertension: Focus on amlodipine/olmesartan combination. Drugs Today (Barc) 44:443-453.
3. Deeks ED (2011) Olmesartan medoxomil/amlodipine/hydrochlorothiazide: Fixed-dose combination in hypertension. Drugs 71:209-220.
4. Ettmayer P, Amidon GL, Clement B, and Testa B (2004) Lessons learned from marketed and investigational prodrugs. J Med Chem 47:2393-2404.
5. Fukami T and Yokoi T (2012) The emerging role of human esterases. Drug Metab Pharmacokinet 27:466-477.
6. Hosokawa M, Endo T, Fujisawa M, Hara S, Iwata N, Sato Y, and Satoh T (1995) Interindividual variation in carboxylesterase levels in human liver microsomes. Drug Metab Dispos 23: 1022-1027.
7. Imai T and Ohura K (2010) The role of intestinal carboxylesterase in the oral absorption of prodrugs. Curr Drug Metab 11:793-805.
8. Ishizuka T, Fujimori I, Kato M, Noji-Sakikawa C, Saito M, Yoshigae Y, Kubota K, Kurihara A, Izumi T, and Ikeda T, et al. (2010) Human carboxymethylenebutenolidase as a bioactivating hydrolase of olmesartan medoxomil in liver and intestine. J Biol Chem 285: 11892-11902.
9. Ishizuka T, Fujimori I, Nishida A, Sakurai H, Yoshigae Y, Nakahara K, Kurihara A, Ikeda T, and Izumi T (2012) Paraoxonase 1 as a major bioactivating hydrolase for olmesartan medoxomil in human blood circulation: Molecular identification and contribution to plasma metabolism. Drug Metab Dispos 40:374-380.
10. Kubo T, Kim SR, Sai K, Saito Y, Nakajima T, Matsumoto K, Saito H, Shirao K, Yamamoto N, and Minami H, et al. (2005) Functional characterization of three naturally occurring single nucleotide polymorphisms in the CES2 gene encoding carboxylesterase 2 (HCE-2). Drug Metab Dispos 33:1482-1487.
11. Laeis P, Püchler K, and Kirch W (2001) The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction. J Hypertens Suppl 19: S21-S32.
12. Leviev I, Negro F, and James RW (1997) Two alleles of the human paraoxonase gene produce different amounts of mRNA. An explanation for differences in serum concentrations of paraoxonase associated with the (Leu-Met54) polymorphism. Arterioscler Thromb Vasc Biol 17: 2935-2939.
13. Liederer BM and Borchardt RT (2006) Enzymes involved in the bioconversion of ester-based prodrugs. J Pharm Sci 95:1177-1195.
14. Lowry OH, Rosebrough NJ, Farr AL, and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
15. Marsillach J, Ferré N, Vila MC, Lligoña A, Mackness B, Mackness M, Deulofeu R, Solá R, Parés A, and Pedro-Botet J, et al. (2007) Serum paraoxonase-1 in chronic alcoholics: Relationship with liver disease. Clin Biochem 40:645-650.
16. Paine MF, Khalighi M, Fisher JM, Shen DD, Kunze KL, Marsh CL, Perkins JD, and Thummel KE (1997) Characterization of interintestinal and intraintestinal variations in human CYP3Adependent metabolism. J Pharmacol Exp Ther 283:1552-1562.
17. Rump LC and Sellin L (2010) Combination therapy for hypertension: Focus on high-dose olmesartan medoxomil (40 mg) plus hydrochlorothiazide. Expert Opin Pharmacother 11: 2231-2242.
18. Satoh T (2005) Toxicological implications of esterases-from molecular structures to functions. Toxicol Appl Pharmacol 207(2, Suppl)11-18.
19. Schwer H, Langmann T, Daig R, Becker A, Aslanidis C, and Schmitz G (1997) Molecular cloning and characterization of a novel putative carboxylesterase, present in human intestine and liver. Biochem Biophys Res Commun 233:117-120.
20. Schwocho LR and Masonson HN (2001) Pharmacokinetics of CS-866, a new angiotensin II receptor blocker, in healthy subjects. J Clin Pharmacol 41:515-527.
21. Scott LJ and McCormack PL (2008) Olmesartan medoxomil: A review of its use in the management of hypertension. Drugs 68:1239-1272.
22. Testa B and Mayer JM (2003) Hydrolysis in Drug and Prodrug Metabolism: Chemistry, Biochemistry, and Enzymology, Wiley-Vch Verlagsgesellschaft Mbh, Zurich.
23. Thasler WE, Weiss TS, Schillhorn K, Stoll PT, Irrgang B, and Jauch KW (2003) Charitable statecontrolled foundation human tissue and cell research: Ethic and legal aspects in the supply of surgically removed human tissue for research in the academic and commercial sector in Germany. Cell Tissue Bank 4:49-56.
24. Thelen K and Dressman JB (2009) Cytochrome P450-mediated metabolism in the human gut wall. J Pharm Pharmacol 61:541-558.
25. von Bergmann K, Laeis P, Püchler K, Sudhop T, Schwocho LR, and Gonzalez L (2001) Olmesartan medoxomil: Influence of age, renal and hepatic function on the pharmacokinetics of olmesartan medoxomil. J Hypertens Suppl 19:S33-S40.
26. Xu G, Zhang W, Ma MK, and McLeod HL (2002) Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan. Clin Cancer Res 8:2605-2611.
27. Yang D, Pearce RE, Wang X, Gaedigk R, Wan YJ, and Yan B (2009) Human carboxylesterases HCE1 and HCE2: Ontogenic expression, inter-individual variability and differential hydrolysis of oseltamivir, aspirin, deltamethrin and permethrin. Biochem Pharmacol 77:238-247.
28. Yoshihara K, Gao Y, Shiga H, Wada DR, and Hisaoka M (2005) Population pharmacokinetics of olmesartan following oral administration of its prodrug, olmesartan medoxomil: In healthy volunteers and hypertensive patients. Clin Pharmacokinet 44:1329-1342.
29. Zhang QY, Dunbar D, Ostrowska A, Zeisloft S, Yang J, and Kaminsky LS (1999) Characterization of human small intestinal cytochromes P-450. Drug Metab Dispos 27:804-809.
30. Zhu HJ, Patrick KS, Yuan HJ, Wang JS, Donovan JL, DeVane CL, Malcolm R, Johnson JA, Youngblood GL, and Sweet DH, et al. (2008) Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: Clinical significance and molecular basis. Am J Hum Genet 82:1241-1248.